Inspire Pharmaceuticals About
Inspire Inspire's
primary focus is in the ophthalmic and respiratory therapeutic areas. Its ophthalmic
products and product candidates are concentrated in the allergic conjunctivitis,
dry eye disease and retinal disease indications The lead product
diquafosol tetrasodium (INS365 Ophthalmic) for the treatment of dry eye
disease Diquafosol tetrasodium is a P2Y2 receptor agonist that activates receptors
on the ocular surface and inner lining of the eyelid to stimulate the release
of water, salt, mucin and lipids - the key components of natural tears. Diquafosol tetrasodium (INS365 Ophthalmic)
for the treatment of dry eye disease INS37217 --Respiratory
(denufosol tetrasodium) for the treatment of cystic
fibrosis INS37217 --Ophthalmic (denufosol tetrasodium) for
the treatment of retinal disease IN50589
--Antiplatelet for
Platelet Inhibition More
on Inspire